Oligomer-Nucleoside Phosphate Conjugates for Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antineoplastic and antiviral agents, such as nucleoside analogs, exhibit significant toxicity and side effects due to their action on normal tissues, and existing treatments for Hepatitis C virus infection are only partially effective with notable side effects.
Innovation Solution
Development of chemically modified nucleoside phosphates conjugated with water-soluble, non-peptidic oligomers, which are designed to reduce metabolism and penetration across biological barriers, thereby minimizing side effects while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside analogs are used as antineoplastic and antiviral agents, then therapeutic efficacy is achieved, but toxicity and side effects on normal tissues increase
Solution Approach 1:
The invention segments the drug molecule by attaching nucleoside phosphate to oligomer chains, creating a modular structure where the nucleoside provides therapeutic activity while the oligomer provides selective targeting and reduced toxicity. This segmentation allows independent optimization of efficacy and safety properties.
Solution Approach 2:
The conjugated structure creates local quality differences: the nucleoside phosphate portion maintains high affinity for viral or cancerous targets, while the oligomer portion provides water solubility and reduced penetration into normal tissues. This local differentiation allows the drug to be highly effective at the target site while minimizing systemic toxicity.
2Reliability
If chemically modified nucleoside phosphates are developed to reduce metabolism, then bioavailability improves, but drug metabolism and clearance may be affected
Solution Approach 1:
The oligomer acts as an intermediary that protects the nucleoside phosphate from rapid metabolism and clearance. The oligomer chain serves as a protective shield that reduces recognition by metabolic enzymes while still allowing the nucleoside portion to interact with its target. This intermediary structure extends drug half-life and improves bioavailability.
3Quantity of substance
If nucleoside phosphates are conjugated with water-soluble oligomers, then water solubility and bioavailability improve, but penetration across biological barriers may be reduced
Solution Approach 1:
The invention changes the physical-chemical parameters of the nucleoside phosphate by conjugating it with hydrophilic oligomers. This increases water solubility and bioavailability while the specific oligomer structure and length are optimized to maintain sufficient penetration capability across biological barriers through parameter optimization.
Data Source
AI summary
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.